Analysis of Clinical Trials on Therapies for Prostate Cancer in Mainland China and Globally from 2010 to 2020

被引:3
|
作者
Chen, Kun [1 ]
Jiang, Kehua [2 ]
Tang, Lannan [2 ]
Chen, Xiaolong [2 ]
Hu, Jianxin [2 ]
Sun, Fa [2 ]
机构
[1] Guizhou Prov Peoples Hosp, NHC Key Lab Pulm Immune Related Dis, Guiyang, Peoples R China
[2] Guizhou Prov Peoples Hosp, Dept Urol, Guiyang, Peoples R China
来源
FRONTIERS IN ONCOLOGY | 2021年 / 11卷
关键词
drug trials; prostate cancer; chemotherapy; gene-targeted; immunotherapy; IMMUNE-CHECKPOINT INHIBITORS; RADIOTHERAPY; STATISTICS;
D O I
10.3389/fonc.2021.647110
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The overall aging of the world population has contributed to the continuous upward trend in the incidence of prostate cancer (PC). Trials on PC therapy have been extensively performed, but no study has analyzed the overall trends and characteristics of these trials, especially for those carried out in China. This study aimed to provide insights on the future direction of drug development in PC, thus supplying essential supportive data for stakeholders, including researchers, patients, investors, clinicians, and pharmaceutical industry. The details of the clinical trials of drug therapies for PC during January 1, 2010, to January 1, 2020, were collected from Pharmaprojects. A total of 463 clinical trials on different therapies with 132 different drugs were completed. The long-acting endocrine therapy with few side effects, radiotherapy combined with immune checkpoint inhibitors, gene-targeted chemotherapeutics, and novel immunotherapeutic products changed the concept of PC treatment. In mainland China, 31 trials with 19 drugs have been completed in the 10 assessment years. China has initiated a few trials investigating a limited number of drug targets, centered in a markedly uneven geographical distribution of leading clinical trial units; hence, the development of PC drugs has a long way to go. Given the large patient pool, China deserves widespread attention for PC drug research and development. These findings might have a significant impact on scientific research and industrial investment.
引用
收藏
页数:9
相关论文
共 50 条
  • [21] Endpoints in prostate cancer clinical trials
    Sartor, O
    UROLOGY, 2002, 60 (3A) : 101 - 107
  • [22] Current Clinical Trials in Prostate Cancer
    Saleh, Naveed
    Copur, Mehmet Sitki
    ONCOLOGY-NEW YORK, 2019, 33 (08): : 330 - 331
  • [23] Hypofractionation in clinical trials for prostate cancer
    Hoskin, P. J.
    Dearnaley, D. P.
    CLINICAL ONCOLOGY, 2007, 19 (05) : 287 - 288
  • [24] Current clinical trials in prostate cancer
    不详
    ONCOLOGY-NEW YORK, 2000, 14 (03): : 396 - +
  • [25] Changes in clinical trials of endocrine disorder and metabolism and nutrition disorder drugs in mainland China over 2010-2019
    Liu, Xin
    Wu, Suqin
    Sun, Jian
    Ni, Suiqin
    Lu, Laichun
    Hu, Wei
    Wei, Hua
    Zou, Yanqin
    Li, Ting
    Li, Jintong
    Mijiti, Bugela
    Fang, PingFei
    Zhao, Limei
    Zhou, Huan
    Xing, Xiaoming
    Niu, Haitao
    Cao, Yu
    PHARMACOLOGY RESEARCH & PERSPECTIVES, 2021, 9 (02):
  • [26] General characteristics and reasons for the discontinuation of drug clinical trials in mainland China
    Huo, Ben-Nian
    Ai, Mao-Lin
    Jia, Yun-Tao
    Liu, Yao
    Wang, Yang
    Yin, Nan-Ge
    Song, Lin
    BMC MEDICAL RESEARCH METHODOLOGY, 2021, 21 (01)
  • [27] A Path to Precision Medicine in Prostate Cancer: Learning from "Negative" Trials of Targeted Therapies
    Dorff, Tanya B.
    Morgans, Alicia K.
    EUROPEAN UROLOGY, 2022, 82 (05) : 516 - 517
  • [28] General characteristics and reasons for the discontinuation of drug clinical trials in mainland China
    Ben-nian Huo
    Mao-lin Ai
    Yun-tao Jia
    Yao Liu
    Yang Wang
    Nan-ge Yin
    Lin Song
    BMC Medical Research Methodology, 21
  • [29] Immune-Based Therapies in Pancreatic Cancer: a Systematic Review of Ongoing Clinical Trials (2020–2022)
    Justine T. Hung
    Ritwick S. Mynam
    Monica A. Patel
    Stanley Ozogbo
    Noelle K. LoConte
    Jeremy D. Kratz
    Journal of Gastrointestinal Cancer, 2025, 56 (1)
  • [30] The design and analysis of clinical trials for group therapies
    Roberts, C
    CONTROLLED CLINICAL TRIALS, 2003, 24 : 72S - 72S